Free tool
FAERS Monitor: Heparin Sodium 25,000 Units In Sodium Chloride 0.45% In Plastic Container
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019953 or its brand name (Heparin Sodium 25,000 Units In Sodium Chloride 0.45% In Plastic Container, Heparin Sodium). Reports on generic versions are filed under their own applications.
Reports
22
Serious
19
86% of reports
Hospitalization
11
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective7
- somnolence6
- abdominal pain5
- asthenia5
- blood test abnormal5
- death5
- fatigue5
- gastrooesophageal reflux disease5
- haemoptysis5
- pulmonary embolism5
- vomiting5
- abdominal distension4
- activated partial thromboplastin time prolonged4
- anaemia4
- aortic stenosis4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2019 | 5 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,137 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| aortic stenosisSignal | 4 | 1099.4 | 452.8 | 3,357 |
| activated partial thromboplastin time prolongedSignal | 4 | 755.9 | 311.4 | 2,307 |
| blood test abnormalSignal | 5 | 340.4 | 157.5 | 1,370 |
| haemoptysisSignal | 5 | 171.4 | 79.3 | 686 |
| gastrooesophageal reflux diseaseSignal | 5 | 59.4 | 27.5 | 232 |
| pulmonary embolismSignal | 5 | 50.3 | 23.3 | 196 |
| abdominal distensionSignal | 4 | 36.6 | 15.1 | 106 |
| somnolenceSignal | 6 | 28.5 | 14.4 | 134 |
| abdominal painSignal | 5 | 20.5 | 9.5 | 75 |
| anaemiaSignal | 4 | 20.1 | 8.3 | 55 |
| astheniaSignal | 5 | 12.7 | 5.9 | 44 |
| vomitingSignal | 5 | 10.2 | 4.7 | 33 |
| fatigueSignal | 5 | 6.1 | 2.8 | 17 |
| deathSignal | 5 | 5.5 | 2.6 | 15 |
| drug ineffectiveSignal | 7 | 5.1 | 2.8 | 20 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.